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Summary.-Cyclophosphamide (Cy) produces an interstitial pneumonitis in CBA
mice. The extent of the lung damage has been quantified by measuring the increase
in ventilation rate over 6 weeks after an i.p. injection of Cy 200,250 and 300 mg/kg. A
dose-dependent response was found. When a preliminary ("priming") dose of Cy at
50 mg/kg was given 7, 9 or 14 days before a single large dose of 250 mg/kg, lung
damage was reduced, as shown by a smaller increase in ventilation rate than in those
receiving 250 mg/kg alone, and this difference was significant (P<0 01) in the Day-14-
and highly significant (P<0-001) in the Day-7-"primed" groups. When primed less
than 7 days before, there was a relative increase in ventilation rate, which was statis-
tically significant (P<0.01) in the Day-i -primed group. Similar effects were also seen
in the survival of the mice.
INTERSTITIAL PNEUMONITIS and pul-
monary fibrosis resulting from cyclo-
phosphamide (Cy) administration in man
is well documented, although it is rare
(Andre et al., 1967; Patel et al., 1976;
Mark et al., 1978). The use of Cy may
however pose more of a clinical problem
by enhancing radiation lung damage
(Phillips & Fu, 1976). Cy has also been
reported to produce consistent lung dam-
age in rats after a single i.p. dose of 200
mg/kg (Gould & Miller, 1975). The histo-
logical changes seen in the rat were similar
to those seen in man, although the damage
occurred within a few days, unlike that in
man, which usually occurs after several
months of administration.
By giving a preliminary small dose of a
cytotoxic agent at a specific interval
before a subsequent large dose of the same
or a different cytotoxic agent, the damage
to normal tissues may be reduced. This
procedure will be called "priming", and
the preliminary small dose referred to as
the "priming dose". Priming with Cy has
been shown to reduce lethality in mice
after total-body irradiation, by enhancing
haemopoietic recovery (Gregory et al.,
1971; Millar & Hudspith, 1976; Blackett
& Aguado, 1979). Cy priming acts by a
similar mechanism to protect against
busulphan toxicity (Millar et al., 1975). Cy
priming has also been shown to increase
mouse survival after a second large dose
of Cy, but neither the cause of death nor
the mechanism of protection could be
explained (Millar & McElwain, 1978).
This is the first study in which the
ventilation rate has been used as a func-
tional assessment of the extent of drug-
induced lung damage. So far as we are
aware, there have also been no previous
reports of protection of the lung from the
toxic effects of anticancer agents by
priming with a cytotoxic drug. Although
pulmonary oedema has been reported
following Cy in BALB/c mice (Berenbaum,
1974) Cy-induced interstitial pneumonitis
has not been previously described in the
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METHODS AND MATERIALS
Twelve-week-old CBA male mice wrere
used throughout the study. Groups of 5 mice
were given Cy monohydrate (Koch-Light
Laboratories) at 200 mg, 250 mg and 300 mg/
kg by i.p. injection. Further groups of 5 mice
were given a priming dose of 50 mg/kg Cy,
from 14 days to 12 h before a second dose of
250 mg/kg. A preliminary experiment had
been carried out, in which the second large
dose was 300 mg/kg.
The ventilation rate wAas measured several
times a week using a whole-body mouse
plethysmograph as described by Travis
et al. (1979a). The mouse was placed in a
perspex chamber of250 ml with a microphone
sealed into it at one end, and a sealed door
at the other end. Air was drawn through the
chamber at 100 ml/min. The signal from the
microphone was amplified and then passed
through filters to exclude signals outside
1-10 Hz, the range of ventilation rates likely
to be encountered. The output wAas passed
through a zero-crossing rate meter and dis-
played by a pen recorder.
The data obtained over the first 5 weeks
were analysed by a two-way analysis of
variance. For each treatment the ventilation
rates were examined over wNeekly periods. The
differences between these periods and between
the treatment groups were analysed. No
significant differences among the times of
assessment were found, but significant differ-
ences among the treatment groups were.
Each set of data was therefore averaged over
the 5-wieek period, and P values obtained for
differences between treatments, using
Student's t test (see results).
Pairs ofmice were killed before, and 1, 2, 3,
and 4 weeks after a dose of 300 mg/kg of Cy.
The lungs were inflated and fixed in formol-
saline, and sections were stained with haema-
toxylin and eosin, Gordon and Sweet's stain
for reticulin and van Giesen's stain for col-
lagen. The red-blood-cell count was measured
w,eekly.
RESULTS
Ventilation rates were measured at
regular intervals for 6 weeks after Cv
administration. The results for 3 different
dose levels are shown in Fig. 1. Control
rates remained within therange 4-5 Hz. In
all treatment groups there was a rise in
I~ 9
4 8
-~~~~~~~~~~~~~~~
DAYS
FiGc. 1. Mlean ventilation rates of groups
of mice treatedl with e.yelopho.sphamidle at
200 mg/kg (sO), 250 mg/kg (0*) andl 300
mg/kg ( O) together wtith unltreatedl con-
trols (A*) measuredl ov-er 6 wreeks after
injection. The lines thlroughl thle mean:s wsere
drawn by eye.
ventilation rate within 3 days. The rate of
rise during the first 7 days after treatment
appeared to increase with dose, and be-
yond 2 weeks the ventilation rate in mice
given the lowest dose (200 mg/kg) de-
clined, while that for the highest dose
(300 mg/kg) continued to increase. A
significant difference (P < 0 001) was found
between the 200mg/kg- and 250mg/kg-
treated groups.
The mean ventilation rates following
250 mg/kg preceded by a single 50mg/kg
priming dose, given 12 h to 14 days
beforehand, are shown ini Fig. 2. In each
panel of this figure the survival of the
treated group of 5 mice is indicated: the
results are clearly less reliable when few
mice survived. Most of the curves show a
first peak in breathing rate at 5-8 days
after the large dose, and in some cases
there is evidence of a second peak at
around one month. The mean ventilation
rates of those mice primed at 7, 9 and 14
days appear generally lower than those of
the unprimed control group, shown in
Fig. 2 as a dashed line. The mean rate of
the 1-day-primed group appears higher.
The mean ventilation rates, averaged
over the 5-week period, are shown in
Fig. 3. It can be seen that there was a
tendency for the mean ventilation rate to
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FIG. 2.-Mean ventilation rates ( + s.e.) of groups treated with a priming dose of 50 mg/kg, from 14
days to 12 h before a second large dose of 250 mg/kg cyclophosphamide. The dashed line in each
graph represents the unprimed group. At the bottom of each graph are plotted the number of mice
surviving. The control group is shown with the Day 14 primed group.
exceed the unprimed control value at
short intervals, and to fall below it at
longer intervals. The values at 7 and 14
days show significant protection (P < 0.01)
and the value at 1 day shows significant
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FIG. 3. Mean ventilation rate over 5 weeks
(± s.e.) following 250 mg/kg cyclophospha-
mide primed by 50 mg/kg at the intervals
shown.
enhancement of response (P < 001). The
change-over from enhancement to pro-
tection occurred at an interval of about
5 days. Similar trends have also been seen
in another experiment, in which the large
dose of Cy was 300 mg/kg.
The numbers of mice surviving at 6
weeks are shown in Fig. 4. Similar trends
are seen in both experiments, with re-
duced lethality in those mice primed 7-14
days beforehand, and in those primed at
12 h. Also shown in Fig. 4 (lower panel) as
a dashed line, are the mean ventilation
rates over the first 5 weeks. The increased
survival in the 7-, .9- and 14-day primed
groups is mirrored by the reduced ventila-
tion rates in these groups, and the poor
survival in the group primed at 1 day
agrees well with the increased ventilation
rate ofthis group. It can also be seen that
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FIcG. 4. Numbers of miee surviving at 6
w-eeks after a large dose of cyclophosplha-
midle (300 mg/kg in the top panel, an(l 250
mg/kg in the bottom panel) botb primedl
wvith 50 mg/kg cyclophosphamide at the
time inteirvals shown. The dashed line rep-
fesents the mean ventilation rates ovxer
5 w\eeks (from Fig. 3).
the increased survival of the 12h-primed
group is associated with a reduction in
ventilation rate, compared to the Day-l-
primed and unprimed groups.
Histological sections of the lung were
examined by light microscopy at 1, 2, 3
and 4 weeks after Cy 300mg/kg. At 1
week there were the typical features of an
acute interstitial pneumonitis. There was
a cellular infiltrate which primarily con-
sisted of neutrophil and basophil leuco-
cytes and plasma cells. There was some
hyperplasia of the granular pneumocytes.
Many of the cells appeared atypical and
the nuclei were hyperchromatic. The
interalveolar walls were thickened, not
only by increased cellularity, but also by
interstitial oedema. In some areas there
was alveolar collapse, although for the
most part the alveolae were patent and
intact.
At 2 weeks, although there was a slight
decrease in the overall cellularity due to a
reduction in the cellular infiltrate, there
was further hyperplasia of the granular
pneumocytes, many appearing enlarged
and with foamy cytoplasm, and some of
these cells sloughing into the alveolar
spaces. Segmental areas of collapse and
consolidation in the right lower lobe were
noted in all the mice killed at 2, 3 and 4
weeks. The alveolar spaces in these areas
were filled with cellular debris and
sloughed epithelial cells. However, there
was no evidence of any polymorpho-
nuclear leucocyte infiltrate. Organization
and early fibrosis were mostly seen in
these areas, and were most marked at 3
and 4 weeks after the drug, although the
overall cellularity was slightly reduced at
this later time.
The red blood cell count was measured
at 1, 2, 3 and 4 weeks after cyclophospha-
mide 300 mg/kg, and no evidence of
anaemia was found.
DISCUSSION
The findings of marked histological
changes similar to those reported in rats
(Gould & Miller, 1975) confirms that Cy
induces pneumonitis in mice as well as in
rats and man (Patel et al., 1976). Although
fibrosis was not prominent in these mice,
they were only examined up to 4 weeks
after administration, and fibrosis may
develop later. It was also found that indi-
vidual mice nearly always have an in-
crease in ventilation rate before death,
which would suggest, if the increase in
ventilation rate is due to lung damage,
that lung damage is the cause of death.
The evidence that an increase in ventila-
tion rate is related to Cy-induced lung
damage is as follows. Firstly, the onset of
tachypnoea coincides with the develop-
inent of histological pneumonitis. Second-
ly, no other causes of tachypnoea, in
particular no evidence of anaemia, were
found. However, cardiac damage, which
has been reported in dogs (O'Connell &
Berenbaum, 1974) was not specifically
excluded. In the dogs, however, the drug
was used in a considerably more toxic
range, since the dogs died within a few
hours of administration, rather than days,
as in these mice. Thirdly, other agents
sX~~~~~~~~~*
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causing lung damage, such as bleomycin
(unpublished data) and irradiation
(Travis et al., 1979a) also increase in
ventilation rates, but drug toxicity or
sickness without lung damage causes a
slowing of ventilation rather than
tachypnoea.
Further evidence indicates a quanti-
tative as well as a qualitative relationship
of ventilation rate to lung damage, i.e.
that the extent of lung damage is related
to the ventilation rate. A scored assess-
ment of histological damage after lung
irradiation has shown that the ventilation
rate correlates well with the extent of
histological damage (Travis et al., 1979b).
In the present study, the highest ventila-
tion rates are seen shortly before death,
when lung damage is maximal. Further-
more, the mean ventilation rate closely
follows the number of mice surviving
(Fig. 4) and, if death is due to lung
damage, the number of mice surviving
reflects the extent of lung damage.
The results show that the mean ven-
tilation rate, and therefore the extent of
the lung damage, was related to the dose
of drug administered, a highly significant
difference in ventilation rates being found
between the 200mg/kg and 250mg/kg
doses. Although there is considerable
overlap between the effects of 250 mg/kg
and 300 mg/kg (as shown in Fig. 1),
clearer separation was seen in earlier
experiments.
An allergic response has been suggested
as a mechanism for cytotoxic drug-
induced lung damage in man, largely
because of its sporadic occurrence and
lack of evidence of dose-dependency in
many instances. However, the histological
changes seen with Cy, and indeed with
most cytotoxic drug-induced lung damage
in man, favours a direct toxic effect
(Sostman et al., 1977). The finding here of
a dose-dependent response lends further
support to a direct toxic effect, rather thaJn
an allergic response.
It was of interest to have examined a
tissue, such as the lung, with a slow cell
turnover, since most of the studies of
normal-tissue protection have been carried
out in rapidly proliferating tissues, such
as marrow and intestine. Mortality due to
bone marrow failure after treatment with
melphalan and busulphan may be re-
duced by priming at 2 days with melpha-
lan or cyclophosphamide respectively
(Jeney et al., 1968). This protection is due
to enhanced recovery of the bone marrow
(Millar et al., 1975). After irradiation,
similar protection ofthe marrow, assessed
by the spleen CFU-S, is optimal with a
slightly longer priming interval of 3 days
with Cy, and 1 day after priming with
cytosine arabinoside (Blackett, personal
communication). Thus the optimal prim-
ing interval varies with the nature of the
priming agent, and probably also with the
principal toxic agent. It may also vary in
different tissues. The gut is protected
against irradiation by cytosine arabino-
side, which acts by a different mechanism
and increases the radioresistance of the
microcolony-forming stem cells: protec-
tion is optimal with priming at 12 h
(Phelps & Blackett, 1979).
The finding of either enhanced or re-
duced lung damage, according to the
priming interval, might be explained in
terms of the proliferating kinetics of the
alveolar epithelium. Although difficult to
relate to the slow cycling times of the un-
perturbed alveolar cells, they may be
related to the kinetics of stimulated
epithelial cells. Adamson & Bowden
(1974) have studied the kinetics and
morphology of epithelial regeneration
following exposure to oxygen, which
causes a proliferative cellular response,
similar to that seen with cyclophospha-
mide, as well as with a number of other
toxic agents. Type II epithelial cells
showed mitotic activity and the peak
mitotic activity occurred between the
second and third day after stopping oxy-
gen, as shown by mitotic arrest with
colchicine and nuclear labelling with
[3H]TdR. The proliferating Type II cells
were calculated to have a generation time
of 3 days, and by 3-4 days after 02 ex-
posure lung morphology had returned to
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normal. On the basis of these results, our
findings may be explained as follows.
When the large dose of Cy follows the
priming dose after 1 or 2 days, a large
number of cells are in cycle and lung
epithelium is particularly sensitive to the
drug. If, however, the large dose is delayed
to 7 days or more, cell division has de-
clined and the resultant increased cell
population renders the lung more tolerant
to the large dose. It is difficult to relate
the probable protection seen with priming
at 12 h to cell kinetics, since for one thing
Cy has not been reported to be phase-
specific. However, protection could be due
to non-kinetic factors, as have been pro-
posed for cytosine arabinoside given 12 h
before gut irradiation (Phelps & Blackett,
1979).
Another interesting effect of Cy on the
lungs of mice, which also depends on the
timing of its administration, is the en-
hanced lung-colony formation after i.v.
injections of tumour cells (van Putten et.
al., 1975; Carmel & Brown, 1977; Steel &
Adams, 1977). In the C3H mice, enhance-
ment was optimal when the drug was given
24 h before the tumour cells (Carmel &
Brown, 1977). CBA mice primed at the
same interval in this study showed maxi-
mal enhancement of lung damage. It may
therefore be that the condition ofthe lung
which makes it more susceptible to Cy
lung damage also makesit moresusceptible
to tumour implantation. Strain differ-
ences make such conclusions speculative
at present, since in C57 mice the optinmal
time for Cy enhancement of lung colonies
is 2-4 days (Steel & Adams, 1977). How-
ever, these particular mice may have
delayed development of lung changes,
since their median survivals following lung
irradiation were between 200 and 310 days,
whereas in CBA mice the medians ranged
from 95 to 130 days, which are similar to
the median survivals reported by other
investigators (Steel et al., 1979).
If the metabolism of Cy and the lung
biology of man and mouse were similar,
Cy lung damage in man would be reduced
by priming with Cy 7 days before the
large dose, and divided doses at intervals
ofbetween 1 and 7 days should perhaps be
avoided. However, the cell kinetics of
human lung and the metabolism of Cy are
different in man and mouse; therefore the
absolute time intervals may need modifi-
cation. In addition man differs from mouse
in that Cy-induced lung damage is un-
usual, presumably because dose-limiting
toxicity develops in other organs first.
None the less lung damage does occur, and
its prevention would be of value.
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